奥瑞珠单抗延长给药间隔在新冠疫情期间的临床影响及其与CD19+B细胞再增殖的关联 - Suppr

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19B-cell repopulation.

作者信息

Sahi Nitin Kumar, Abidi Syed Muhammad Ali, Salim Omar, Abraham Roby, Kalra Seema, Al-Araji Adnan

机构信息

Royal Stoke MS Centre, University Hospitals of North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent ST4 6QG, United Kingdom.

出版信息

Mult Scler Relat Disord. 2021 Nov;56:103287. doi: 10.1016/j.msard.2021.103287. Epub 2021 Sep 27.

DOI:10.1016/j.msard.2021.103287

PMID:34627005

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8474870/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5628/8474870/5cf5f0755050/gr1_lrg.jpg

相似文献

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19B-cell repopulation.奥瑞珠单抗延长给药间隔在新冠疫情期间的临床影响及其与CD19+B细胞再增殖的关联

Mult Scler Relat Disord. 2021 Nov;56:103287. doi: 10.1016/j.msard.2021.103287. Epub 2021 Sep 27.

Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?多发性硬化症个体化奥瑞珠单抗治疗：我们能从 SARS-CoV2 大流行中学到什么？

J Neurol Sci. 2021 Aug 15;427:117501. doi: 10.1016/j.jns.2021.117501. Epub 2021 May 20.

The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.奥瑞珠单抗治疗多发性硬化症患者的药效减退现象。

Mult Scler Relat Disord. 2022 Jan;57:103364. doi: 10.1016/j.msard.2021.103364. Epub 2021 Nov 1.

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.COVID-19 大流行时期多发性硬化症奥瑞珠单抗延长给药间隔

Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5). doi: 10.1212/NXI.0000000000001035. Print 2021 Sep.

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.COVID-19 大流行期间多发性硬化症患者奥瑞珠单抗的个性化 B 细胞靶向剂量调整。

Mult Scler. 2022 Jun;28(7):1121-1125. doi: 10.1177/13524585211028833. Epub 2021 Jul 9.

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.由于 COVID-19 大流行而延迟奥瑞珠单抗治疗多发性硬化症对临床和实验室疗效的影响。

Mult Scler Relat Disord. 2021 Feb;48:102704. doi: 10.1016/j.msard.2020.102704. Epub 2020 Dec 21.

Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab.了解奥瑞珠单抗治疗多发性硬化症患者中 COVID-19 大流行的影响。

Mult Scler Relat Disord. 2021 Oct;55:103203. doi: 10.1016/j.msard.2021.103203. Epub 2021 Aug 8.

Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis.奥瑞珠单抗浓度和抗药物抗体与多发性硬化症中的B细胞计数相关。

J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):487-493. doi: 10.1136/jnnp-2022-330793. Epub 2023 Jan 24.

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.一名多发性硬化症患者在大流行期间开始使用奥瑞珠单抗治疗，感染新冠病毒后预后良好。

Mult Scler Relat Disord. 2020 Aug;43:102222. doi: 10.1016/j.msard.2020.102222. Epub 2020 May 23.

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.使用奥瑞珠单抗治疗的多发性硬化症患者中COVID-19的良性病程。

Mult Scler Relat Disord. 2020 Jul;42:102201. doi: 10.1016/j.msard.2020.102201. Epub 2020 May 15.

引用本文的文献

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.多发性硬化症抗CD20治疗的演变：抗体特性与功能的优化

CNS Drugs. 2025 Jun;39(6):545-564. doi: 10.1007/s40263-025-01182-8. Epub 2025 Apr 3.

De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: An initial Iranian experience.复发缓解型多发性硬化症患者抗CD20单克隆抗体降阶梯至低-中度疗效疾病修正治疗（DMTs）：伊朗的初步经验。

Caspian J Intern Med. 2024 Oct 19;16(1):126-131. doi: 10.22088/cjim.16.1.126. eCollection 2025 Winter.

MS treatment de-escalation: review and commentary.多发性硬化症治疗的逐步降级：综述与评论

J Neurol. 2024 Oct;271(10):6426-6438. doi: 10.1007/s00415-024-12584-x. Epub 2024 Aug 2.

Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study.复发缓解型多发性硬化症中奥瑞珠单抗的计划剂量减少：一项单中心观察性研究

BMJ Neurol Open. 2024 Jun 21;6(1):e000672. doi: 10.1136/bmjno-2024-000672. eCollection 2024.

Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.奥瑞珠单抗延长给药间隔在多发性硬化症中的临床和免疫学影响：单中心真实世界经验。

Int J Mol Sci. 2024 May 14;25(10):5353. doi: 10.3390/ijms25105353.

The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.奥瑞珠单抗失效现象与多发性硬化症中的免疫调节反应降低和神经轴突损伤增加有关。

J Neurol. 2024 Aug;271(8):5012-5024. doi: 10.1007/s00415-024-12434-w. Epub 2024 May 23.

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.多发性硬化症中靶向 CD20 的药物：药理学、疗效、安全性和耐受性。

Drugs. 2024 Mar;84(3):285-304. doi: 10.1007/s40265-024-02011-w. Epub 2024 Mar 14.

COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.意大利的 COVID-19 疫情：评估奥瑞珠单抗在多发性硬化症患者中延长间隔给药的机会。

J Neurol. 2024 Feb;271(2):699-710. doi: 10.1007/s00415-023-12084-4. Epub 2023 Nov 20.

Era of COVID-19 in Multiple Sclerosis Care.COVID-19 时代下的多发性硬化症护理。

Neurol Clin. 2024 Feb;42(1):319-340. doi: 10.1016/j.ncl.2023.06.006. Epub 2023 Jun 23.

Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.奥瑞珠单抗延长间隔给药治疗原发性进行性多发性硬化症：意大利经验。

Curr Neuropharmacol. 2024;22(2):339-345. doi: 10.2174/1570159X22666231002142709.

本文引用的文献

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.疾病修正疗法与多发性硬化症中 COVID-19 严重程度的关联。

Neurology. 2021 Nov 9;97(19):e1870-e1885. doi: 10.1212/WNL.0000000000012753. Epub 2021 Oct 5.

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.COVID-19 大流行时期多发性硬化症奥瑞珠单抗延长给药间隔

Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5). doi: 10.1212/NXI.0000000000001035. Print 2021 Sep.

Mult Scler. 2022 Jun;28(7):1121-1125. doi: 10.1177/13524585211028833. Epub 2021 Jul 9.

Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.COVID-19 对多发性硬化症护理和管理的影响：来自欧洲多发性硬化症治疗与研究委员会调查的结果。

Mult Scler. 2022 Jan;28(1):132-138. doi: 10.1177/13524585211005339. Epub 2021 Mar 25.

Mult Scler Relat Disord. 2021 Feb;48:102704. doi: 10.1016/j.msard.2020.102704. Epub 2020 Dec 21.

Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.COVID-19 大流行对 1000 多名多发性硬化症患者的医疗保健的影响：一项横断面研究。

Mult Scler Relat Disord. 2020 Nov;46:102512. doi: 10.1016/j.msard.2020.102512. Epub 2020 Sep 19.

Tailoring B cell depletion therapy in MS according to memory B cell monitoring.根据记忆 B 细胞监测结果调整多发性硬化症中的 B 细胞耗竭疗法。

Neurol Neuroimmunol Neuroinflamm. 2020 Aug 4;7(5). doi: 10.1212/NXI.0000000000000845. Print 2020 Sep.

COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.COVID-19 疫苗接种准备与自身免疫性疾病中的抗 CD20 耗竭疗法。

Clin Exp Immunol. 2020 Nov;202(2):149-161. doi: 10.1111/cei.13495. Epub 2020 Aug 1.

The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.奥瑞珠单抗II期扩展试验表明了改善多发性硬化症风险效益比的潜力。

Mult Scler Relat Disord. 2020 Sep;44:102279. doi: 10.1016/j.msard.2020.102279. Epub 2020 Jun 8.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19B-cell repopulation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献